FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry, and concerns a method of increasing a shelf life of a parenteral pharmaceutical composition containing glucagonlike peptide, its analogue or derivative analogue. The composition is prepared of an unprepacked finished peptide product which has been processed at pH within the range 8.1 to 11.5, and an unprepacked finished peptide product prepared by lyophilisation of a solution or a suspension of said peptide at specified pH.
EFFECT: invention provides higher product stability.
27 cl, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF LONG-ACTING GLP-1 PEPTIDES | 2013 |
|
RU2657573C2 |
| STABLE PREPARATIONS OF INSULIN PEPTIDES | 2005 |
|
RU2413530C2 |
| ACYLATED DERIVATIVE OF GLP-1 | 2019 |
|
RU2773242C2 |
| PEPTIDE COMPOSITION CONTAINING PROPYLENE GLYCOL OPTIMAL FOR MANUFACTURING AND APPLICATION IN INJECTION DEVICES | 2004 |
|
RU2421238C2 |
| DIPEPTIDE, CONTAINING NONPROTEINOGENIC AMINO ACID | 2012 |
|
RU2643515C2 |
| STABLE NON-AQUEOUS PHARMACEUTICAL COMPOSITIONS | 2008 |
|
RU2472492C2 |
| PHARMACEUTIC FORMULATION FOR NASAL ABSORPTION | 2002 |
|
RU2327484C2 |
| PEG-MODIFIED EXENDIN OR EXENDIN ANALOGUE AND ITS COMPOSITIONS AND USE | 2007 |
|
RU2498814C2 |
| COMPOSITION FOR TREATING DIABETES, CONTAINING LONG-ACTING INSULIN CONJUGATE AND LONG-ACTING INSULINOTROPIC PEPTIDE CONJUGATE | 2012 |
|
RU2606840C2 |
| INSULINOTROPIC PEPTIDE DERIVATIVE WITH MODIFIED N-TERMINAL CHARGE | 2014 |
|
RU2673179C2 |
